Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in frontline primary plasma cell leukemia (EUMELEIA)
NCT06636552Phase 2Recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- Nov 2021
- Primary completion
- Jan 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in plasma cell leukaemia (PCL), sponsored by Hellenic Society of Hematology. Started Nov 2021; status: recruiting.
02
Drugs
daratumumab
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on NCT06636552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636552.